Final results of multicenter prospective observational study of nano-liposomal irinotecan, fluorouracil and folinic acid in second-line chemotherapy for advanced pancreatic cancer: The NAPOLEON-2

被引：0

作者：

Toyodome, K. ^{[1
]}

Arima, S. ^{[1
]}

Shimokawa, M. ^{[2
]}

Otsuka, T. ^{[3
]}

Nakazawa, J. ^{[4
]}

Shimokawa, H. ^{[5
]}

Koga, F. ^{[6
]}

Oda, H. ^{[7
]}

Takeshita, S. ^{[8
]}

Kawaguchi, Y. ^{[9
]}

Arita, S. ^{[10
]}

Nishikawa, K. ^{[11
]}

Jikuya, K. ^{[12
]}

Sakai, T. ^{[13
]}

Sawase, H. ^{[14
]}

Ueda, Y. ^{[15
]}

Araki, N. ^{[16
]}

Shirakawa, T. ^{[17
]}

Mizuta, T. ^{[18
]}

Mitsugi, K. ^{[19
]}

机构：

[1] Kagoshima Univ, Digest & Lifestyle Dis, Grad Sch Med & Dent Sci, Kagoshima, Japan

[2] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Yamaguchi, Japan

[3] Minato Med Clin, Dept Internal Med, Fukuoka, Japan

[4] Kagoshima City Hosp, Dept Med Oncol, Kagoshima, Japan

[5] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Fukuoka, Japan

[6] Saga Ken Med Ctr Koseikan, Dept Hepatobiliary & Pancreatol, Saga, Japan

[7] Saiseikai Kumamoto Hosp, Div Integrat Med Oncol, Kumamoto, Fukuoka, Japan

[8] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Gastroenterol, Nagasaki, Japan

[9] Asakura Med Assoc Hosp, Dept Gastroenterol, Fukuoka, Japan

[10] Miyazaki Prefectural Miyazaki Hosp, Dept Chemotherapy, Miyazaki, Japan

[11] Oita Univ, Dept Med Oncol & Hematol, Fac Med, Oita, Japan

[12] Imamura Gen Hosp, Dept Gastroenterol, Kagoshima, Japan

[13] Natl Hosp Org Kumamoto Med Ctr, Dept Med Oncol, Kumamoto, Japan

[14] Natl Hosp Org Saga Hosp, Dept Internal Med, Saga, Japan

[15] Japanese Red Cross Kumamoto Hosp, Dept Hematol & Oncol, Kumamoto, Japan

[16] Saiseikai Sendai Hosp, Dept Gastroenterol, Kagoshima, Japan

[17] Clin Hematol Oncol Treatment Study Grp, Fukuoka, Japan

[18] Fujikawa Hosp, Dept Internal Med, Saga, Japan

[19] Sasebo Kyosai Hosp, Dept Med Oncol, Nagasaki, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.488

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

346P

引用

页码：S144 / S144

页数：1

共 50 条

[31] Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study
Iwamoto, Shigeyoshi
Hazama, Shoichi
Kato, Takeshi
Miyake, Yasuhiro
Fukunaga, Mutsumi
Matsuda, Chu
Bando, Hiroyuki
Sakamoto, Junichi
Oba, Koh
Mishima, Hideyuki
ANTICANCER RESEARCH, 2014, 34 (04) : 1967 - 1973
[32] Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Muro, Kei
Boku, Narikazu
Shimada, Yasuhiro
Tsuji, Akihito
Sameshima, Shinichi
Baba, Hideo
Satoh, Taroh
Denda, Tadamichi
Ina, Kenji
Nishina, Tomohiro
Yamaguchi, Kensei
Takiuchi, Hiroya
Esaki, Taito
Tokunaga, Shinya
Kuwano, Hiroyuki
Komatsu, Yoshito
Watanabe, Masahiko
Hyodo, Ichinosuke
Morita, Satoshi
Sugihara, Kenichi
LANCET ONCOLOGY, 2010, 11 (09) : 853 - 860
[33] FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis from the nation-wide multicenter observational study (JASPAC06)
Kobayashi, N.
Omae, K.
Horita, Y.
Ueno, H.
Mizuno, N.
Uesugi, K.
Sudo, K.
Ozaka, M.
Hayashi, H.
Okano, N.
Kamei, K.
Yamaguchi, A.
Kobayashi, S.
Suzuki, S.
Ishihara, S.
Uchiyama, T.
Todaka, A.
Fukutomi, A.
ANNALS OF ONCOLOGY, 2017, 28
[34] Role of second-line chemotherapy in advanced pancreatic cancer and its influence on phase II/III study results
Teo, M.
McDermott, R. S.
ANNALS OF ONCOLOGY, 2013, 24 (09) : 2462 - 2463
[35] A prospective, multicenter, observational study of bevacizumab in combined with chemotherapy as first-line or second-line treatment in Chinese metastatic colorectal cancer
Qin, Shukui
Deng, Yanhong
Bi, Feng
Liu, Tian Shu
Liu, Yunpeng
Zhang, Suzhan
Xu, Jianming
Shu Yongqian
Xu, Nong
Wu, Changping
Wang, Xin
Zhong, Haijun
Feng, Jifeng
He, Yulong
Yang, Jianwei
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[36] Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study
Hofheinz, RD
Gnad-Vogt, U
Wein, A
Saussele, S
Kreil, S
Pilz, L
Hehlmann, R
Hochhaus, A
ANTI-CANCER DRUGS, 2005, 16 (01) : 39 - 45
[37] Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: A Korean single-center experience
Park, SH
Sung, JY
Han, SH
Baek, JH
Oh, JH
Bang, SM
Cho, EK
Shin, DB
Lee, JH
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (09) : 531 - 535
[38] A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
Pijnappel, Esther
de Vos-Geelen, Judith
Macarulla Mercade, Teresa
Melisi, Davide
Pfeiffer, Per
Prager, Gerald W.
Van Laarhoven, Hanneke W. M.
Wilmink, Johanna
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[39] Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan
Ziras, N.
Potamianou, A.
Varthalitis, I.
Syrigos, K.
Tsousis, S.
Boukovinas, I.
Tselepatiotis, E.
Christofillakis, C.
Georgoulias, V.
ONCOLOGY, 2006, 70 (02) : 106 - 114
[40] Second-Line Chemotherapy With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI Regimen) in Patients With Advanced Small Bowel Adenocarcinoma After Failure of First-Line Platinum-Based Chemotherapy A Multicenter AGEO Study
Zaanan, Aziz
Gauthier, Melanie
Malka, David
Locher, Christophe
Gornet, Jean-Marc
Thirot-Bidault, Anne
Tougeron, David
Taieb, Julien
Bonnetain, Franck
Aparicio, Thomas
CANCER, 2011, 117 (07) : 1422 - 1428

← 1 2 3 4 5 →